Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ACVR2A
REST API REST API
Homo sapiens
ACVR2A is differentially expressed in 286 experiments: 117 organism parts: bone marrow, lung, ... (115 more);, 150 disease states: normal, acute myeloid leukemia, ... (148 more);, 91 cell types 315 cell lines 39 compound treatments and 67 other conditions.
Synonyms ACTRII, ACVR2
Orthologs AVR2A_CHICK (Gallus gallus)   Acvr2a (Rattus norvegicus)   AVR2A_BOVIN (Bos taurus)   Q4H2P9_CIOIN (Ciona intestinalis)   ACVR2A (2 of 2) (Danio rerio)   acvr2a (Danio rerio)   Acvr2a (Mus musculus)   put (Drosophila melanogaster)   acvr2a (Xenopus laevis)   ACVR2A (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, transmembrane receptor protein serine/threonine kinase activity, protein binding, cytoplasm, membrane, BMP signaling pathway, activin receptor signaling pathway, transmembrane receptor protein serine/threonine kinase signaling pathway, metal ion binding, activin binding, spermatogenesis, male gonad development, protein tyrosine kinase activity, ATP binding, regulation of BMP signaling pathway, transferase activity, transferring phosphorus-containing groups, protein self-association, integral to plasma membrane, mesoderm development, receptor activity, nucleotide binding, protein serine/threonine kinase activity, positive regulation of activin receptor signaling pathway, determination of left/right symmetry, protein kinase activity, receptor signaling protein serine/threonine kinase activity, positive regulation of erythrocyte differentiation, coreceptor activity, regulation of nitric-oxide synthase activity, inhibin beta-B binding, penile erection, gastrulation with mouth forming second, positive regulation of bone mineralization, inhibin-betaglycan-ActRII complex, positive regulation of follicle-stimulating hormone secretion, embryonic skeletal system development, inhibin beta-A binding, activin receptor activity, type II, growth factor binding, Sertoli cell proliferation, positive regulation of osteoblast differentiation, response to organic substance, sperm ejaculation, protein phosphorylation, positive regulation of protein phosphorylation, transforming growth factor beta-activated receptor activity, activin-activated receptor activity, anterior/posterior pattern specification
InterPro Term Activin_rcpt, Prot_kinase_cat_dom, Activin_II/TGFBeta-II_recpt, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P27037, B4DWQ2
Search EB-eye ENSG00000121989
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (38 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
MOLT4
2
E-MTAB-37, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
HCC2935
1
E-MTAB-62
HCC1599
1
E-MTAB-37
309 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-21909, ... (52 experiments)

Factor Value U/D Experiments
endothelial cell
3
E-GEOD-3920, E-GEOD-19240, E-GEOD-3998
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18147
ZAP-70+CD38+
1
E-GEOD-4392
ZAP-70-CD38-
1
E-GEOD-4392
plasmacytoid dendritic cell
1
E-TABM-34
85 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-1869, E-MEXP-2069, ... (48 experiments)

Factor Value U/D Experiments
control
3
E-GEOD-8121, E-GEOD-16363, E-GEOD-20295
glioblastoma
3
E-GEOD-4290, E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MEXP-2034, E-GEOD-96
acute lymphoblastic leukemia
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
144 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (26 experiments)

Factor Value U/D Experiments
placebo
2
E-MEXP-1327, E-MEXP-1335
ethanol
2
E-MEXP-2241, E-GEOD-3113
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
control - keratinocyte growth factor
1
E-GEOD-7216
interleukin-24 (Homo sapiens)
1
E-GEOD-7216
M-CSF
1
1
E-GEOD-5099
33 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
GTE6
1
E-GEOD-21521
LT6
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21589, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19018, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-GEOD-1561, E-TABM-147, ... (8 experiments)

Environmental stress
studied in E-GEOD-1643

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-21750, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-10315, E-MEXP-1273, E-MEXP-1220, E-GEOD-13073, ... (13 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-TABM-740, E-GEOD-1926, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-17400

Injury
studied in E-GEOD-19743

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428 ... (5 experiments)

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.574 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM